Matinas BioPharma Holdings (NYSEAMERICAN:MTNB) saw a large growth in short interest during the month of March. As of March 29th, there was short interest totalling 1,406,886 shares, a growth of 7.5% from the March 15th total of 1,308,442 shares. Based on an average daily trading volume, of 280,828 shares, the short-interest ratio is currently 5.0 days. Currently, 1.9% of the company’s stock are short sold.
Separately, Maxim Group set a $6.00 price target on Matinas BioPharma and gave the stock a “buy” rating in a report on Monday, March 19th.
Matinas BioPharma stock opened at $0.66 on Thursday. Matinas BioPharma has a fifty-two week low of $0.59 and a fifty-two week high of $3.20.
Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its earnings results on Monday, March 26th. The company reported ($0.03) earnings per share for the quarter. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. The firm had revenue of $0.05 million during the quarter.
Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC lifted its holdings in shares of Matinas BioPharma by 126.0% in the 4th quarter. Virtu Financial LLC now owns 106,146 shares of the company’s stock valued at $123,000 after purchasing an additional 59,188 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Matinas BioPharma in the 4th quarter valued at about $155,000. Yellowstone Partners LLC purchased a new stake in shares of Matinas BioPharma in the 3rd quarter valued at about $190,000. Deutsche Bank AG lifted its holdings in shares of Matinas BioPharma by 184.8% in the 4th quarter. Deutsche Bank AG now owns 148,042 shares of the company’s stock valued at $171,000 after purchasing an additional 96,054 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of Matinas BioPharma by 3.4% in the 4th quarter. BlackRock Inc. now owns 2,530,508 shares of the company’s stock valued at $2,935,000 after purchasing an additional 84,226 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/04/19/matinas-biopharma-holdings-mtnb-short-interest-up-7-5-in-march.html.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in the United States. It develops orally delivered therapeutics based on cochleate delivery technology, a proprietary lipid-based drug delivery platform.
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.